Pieris Pharmaceuticals, Inc. (PIRS) Covered Calls
You can sell covered calls on Pieris Pharmaceuticals, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for PIRS (prices last updated Fri 4:16 PM ET):
| Pieris Pharmaceuticals, Inc. (PIRS) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 0.14 | -0.01 | 0.15 | 0.15 | 1.9M | - | 0.0 |
| Covered Calls For Pieris Pharmaceuticals, Inc. (PIRS) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| May 17 | 2.5 | 0.00 | 0.15 | 0.0% | 0.0% | |
| Jun 21 | 2.5 | 0.00 | 0.15 | 0.0% | 0.0% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
| Top 10 Open Interest For May 17 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | HYG covered calls | 6. | KWEB covered calls | 1. | CVNA covered calls | |
| 2. | IWM covered calls | 7. | EEM covered calls | 2. | FSLY covered calls | |
| 3. | FXI covered calls | 8. | SLV covered calls | 3. | CLSK covered calls | |
| 4. | QQQ covered calls | 9. | TSLA covered calls | 4. | MARA covered calls | |
| 5. | SPY covered calls | 10. | EWZ covered calls | 5. | EYPT covered calls | |
Want more examples? PIPR Covered Calls | PIZ Covered Calls
